What Syndros Treats: Main Uses and Benefits

Syndros is primarily used to address symptoms related to heightened physiological activity, such as nausea and vomiting, linked to cancer chemotherapy in adult patients. It is specifically applied in clinical settings that involve acute or unstable symptom patterns, where these distressing manifestations have persisted or did not achieve sufficient relief from conventional antiemetic treatments.

This application provides support that helps ease the overall symptom burden of emesis and contributes to improved comfort during periods of heightened symptoms. The medication is also commonly used to help with chronic loss of appetite (anorexia) associated with involuntary weight loss (wasting syndrome) in adult patients with Acquired Immune Deficiency Syndrome (AIDS).

The official therapeutic indications center on two major areas: nausea and vomiting that persists despite conventional treatments and AIDS-related anorexia and weight loss. This use may assist with appetite stimulation, which helps promote food intake and helps maintain a sense of stability when symptoms are more noticeable during the course of a chronic illness.

---

Quick Fact: Relief for Key Symptoms
Symptom Cluster Focus	Nausea and vomiting; Wasting syndrome (anorexia)
Typical Contexts	Oncology supportive care; HIV/AIDS management
Primary Patient Benefit	Supports the management of appetite suppression; Contributes to easing the overall symptom load

Regulatory References

1. U.S. National Library of Medicine’s DailyMed database

Syndros is a prescription medication whose eligibility is strictly defined by regulatory guidelines, limiting its use to adults for approved indications, while explicitly prohibiting use in certain groups.

Contraindicated Populations (Absolute Exclusion)

Syndros must not be used by individuals who meet any of the following criteria, as documented in official prescribing information:

• Patients with a known hypersensitivity (allergy) to the active ingredient, dronabinol, or to alcohol, which is an excipient in the oral solution.
• Patients who are currently receiving, or have received, any product containing disulfiram or metronidazole within the past 14 days.

Age- and Condition-Based Restrictions

Population Group	Eligibility Status in Regulatory Documents
Pediatric Patients	Safety and effectiveness have not been established. Use is specifically avoided in preterm neonates.
Geriatric Patients	May be more sensitive to neurological and blood pressure effects. Consideration of a lower starting amount is advised.
Pregnancy / Lactation	Use should be avoided in pregnant women. Breastfeeding is not recommended during treatment and for a period afterward.
Psychiatric History	Use should generally be avoided in patients with a history of psychiatric disorders (e.g., schizophrenia, mania).
Seizure History	Requires a careful weighing of the potential risks versus the benefits before prescription.

Eligibility is limited strictly to adults who require treatment for anorexia associated with weight loss in AIDS or for nausea and vomiting related to cancer chemotherapy that has not responded adequately to other treatments.

Interactions with Other Medicines and Products

Official regulatory information outlines several categories of products that may interact with Syndros, requiring careful management or complete avoidance.

Interacting Product Category	Official Constraint/Requirement
Disulfiram or Metronidazole	Use is contraindicated due to the ethanol content in Syndros oral solution, which can cause a disulfiram-like reaction. The official labeling mandates stopping these products at least 14 days before starting Syndros, and avoiding them for 7 days after the last dose.
CYP2C9 or CYP3A4 Inhibitors/Inducers	These agents may alter the systemic exposure of dronabinol. Monitoring is required for an increase in dronabinol-related adverse reactions (with inhibitors) or a reduction in efficacy (with inducers).
Highly Protein-Bound Drugs	Potential for displacement of other highly protein-bound drugs, especially those with a narrow therapeutic index (e.g., warfarin, cyclosporine, amphotericin B). Close monitoring is required for adverse reactions related to increased concentrations of the concomitant drug.
CNS Depressants	Concomitant use may result in additive central nervous system effects. This category includes barbiturates, benzodiazepines, and certain antihistamines.
Drugs with Similar Cardiac Effects	Concomitant use may lead to additive hemodynamic instability (e.g., hypotension, hypertension, or tachycardia). This requires monitoring for hemodynamic changes upon initiation or dosage increase of Syndros.

This structure ensures healthcare providers are aware of critical timing restrictions, pharmacokinetic changes that necessitate monitoring of blood concentrations, and pharmacodynamic risks related to additive CNS and cardiovascular effects, all based strictly on governmental regulatory documents.

How Syndros Works: Mechanism of Action

Syndros (dronabinol) is a synthetic compound that acts as an agonist on the Cannabinoid Receptor Type 1 ( CB1), a primary target in the body's endocannabinoid system.

By binding to and activating these receptors, the drug modulates specific neural signaling pathways in the central nervous system. This molecular action leads to two key physiological consequences: the central modulation of signaling in appetite centers and the influence on the neural pathways controlling the emetic reflex.

---

Modulating the Endocannabinoid System via CB1 Receptors

This mechanism involves the drug's molecular interaction with CB1 receptors located on neurons, which initiates the entire downstream cascade. This interaction modulates activity in the pathways where the receptors are present, resulting in changes to both the signaling associated with hunger and the body's emetic response.

---

Central Regulation of Appetite and Emetic Control

The CB1 activity alters signaling in key anatomical regions in the brain, including the hypothalamus (an appetite center) and the brainstem's emetic control centers. By modulating these specific central nervous system pathways, the drug alters activity in appetite pathways and simultaneously influences the neural signals originating in the emetic control centers.

Administration Overview

Syndros is an oral solution that is typically administered using a calibrated oral dosing syringe. To ensure accurate measurement, the prescribed amount is drawn from the bottle using the provided device. It is important to review the markings on the syringe to confirm the correct volume before administration.

Timing and Food Intake

This medication can be taken with or without food. However, consistency is important for maintaining stable levels in the body. If the medication is used to manage symptoms related to appetite, it is often administered at specific times relative to meals. Changes in dietary habits or the timing of doses may affect how the body processes the solution.

Handling and Storage

The solution should be kept in its original container to protect it from light and environmental factors. Proper storage involves maintaining the bottle at the temperature range specified on the product packaging. After each use, the cap should be securely fastened, and the dosing syringe should be cleaned according to the manufacturer's guidelines to maintain hygiene and accuracy for subsequent uses.

Research Evidence / Overview of Studies for Syndros

This overview describes the types of clinical studies conducted for Syndros (dronabinol oral solution), what outcomes those studies monitored, and where the official scientific literature notes limitations or gaps in the evidence. This information is provided for context and is not a substitute for medical advice.

---

Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Research exploring how symptoms change over time for chemotherapy-induced nausea and vomiting primarily consists of short-term randomized controlled trials (RCTs) and systematic reviews. These studies were applied in research contexts focusing on adult cancer patients whose symptoms persisted or did not achieve sufficient relief from other standard treatments.

Studies monitored outcomes related to episodic or acute changes, such as whether outcomes related to the absence of vomiting and retching were measured and the frequency with which patients needed to use rescue medications. Findings describe patterns observed in the studies and are relevant in trials assessing short-term symptom patterns, typically only covering the duration of one chemotherapy cycle.

What remains uncertain is the availability of research comparing the findings to the standard antiemetic regimens in use today.

---

Evidence for Use in AIDS-Related Appetite Loss and Weight Loss

The evidence base for Dronabinol's use in patients with chronic loss of appetite (anorexia) and involuntary weight loss (wasting syndrome) associated with AIDS involves both controlled, intermediate-term studies and subsequent longer, open-label research. Research examined outcomes related to systemic or functional imbalance, primarily monitoring changes in appetite stimulation (using patient-reported tools) and changes in body weight over the study period.

Studies reported how symptoms evolved in the observed populations, and research highlights changes measured during the study period, including those related to appetite. Studies monitored weight measurements also, often over an initial six-week period.

What remains uncertain is whether the results apply equally to patients receiving the highly active antiretroviral therapy (HAART), which became standard after the core studies were completed.

---

Gaps in Research and Areas of Uncertainty

The research provides context, but the overall evidence base includes noted limitations. Comparative evidence is lacking for Dronabinol against current standards of care for CINV. Long-term outcomes are not well characterized for all effects, and many core studies are older, meaning the results apply only to the specific populations and conditions under which they were conducted. Additionally, findings related to weight change do not fully characterize the composition of the weight gained.

---

Evidence in Special Populations

The research primarily covers adult patient populations. Data for certain groups remain insufficient, and specific, limited information is available for the use of this medicine in populations such as pediatric patients (children), and comparative evidence is lacking regarding its use in various comorbidity-defined groups.

Key Studies & References

1. Treatment of AIDs-related anorexia and weight loss was proven effective in a randomized, double-blind, placebo-controlled study with 139 patients. (Referenced in StatPearls/NIH Monograph)
2. Long-Term Dronabinol Use Safe, Effective for AIDS Anorexia (Open-label extension study abstract, J Pain Symptom Manage 14:7-14, 1997)

Common questions about Syndros (FAQ)

---

Q: Does Syndros contain any alcohol, and is this a concern for certain patients?

Official labeling states that Syndros oral solution contains 50% (w/w) dehydrated alcohol as an excipient. This ingredient is noted in the regulatory documents because it can cause an adverse reaction when taken with certain other medicines, specifically disulfiram or metronidazole, leading to a required contraindication.

---

Q: What are the signs of a potential allergic reaction to the ingredients in Syndros?

Reported signs of a potential hypersensitivity (allergic) reaction to the active ingredient, dronabinol, include hives, lip swelling, throat tightness, and a general rash or skin burning. The official product information specifies that the medicine is contraindicated in patients with a known hypersensitivity to the drug or its components.

---

Q: Does Syndros affect a person's ability to drive or operate machinery?

Regulatory information addresses this topic. It advises that individuals should not operate motor vehicles or other dangerous machinery until they are reasonably certain that Syndros does not affect their physical or mental abilities adversely. The advisory is based on the potential for central nervous system effects.

---

Q: Does Syndros help with pain management, or is it strictly for appetite and nausea?

According to the official product information, Syndros is approved for the treatment of anorexia associated with weight loss in patients with AIDS and for nausea and vomiting associated with cancer chemotherapy. Pain management is not listed as one of the drug's two approved indications.

---

Q: Can children or adolescents use Syndros for chemotherapy-related nausea?

The safety and effectiveness of Syndros in pediatric patients (children and adolescents) have not been established in official regulatory documents. Warnings advise that pediatric patients may be more sensitive to the neurological and psychoactive effects of the drug.

---

Q: Is the psychoactive effect ('feeling high') common with the standard prescribed dose of Syndros?

The official product information lists Euphoria (an altered mental state) as a common adverse reaction, reported in 3% or more of patients during clinical trials. This is generally noted in the regulatory documents as one of the central nervous system effects associated with the medicine.

---

Q: What is the purpose of drinking water after taking the Syndros oral solution?

Official administration instructions mandate taking the dose with a full glass of water (6 to 8 ounces) immediately after taking the oral solution. This step is specified in the regulatory instructions to ensure proper administration of the liquid medicine.

---

Q: How does the mg/m² CINV dosing work?

The mg/m^2 dosage for chemotherapy-induced nausea and vomiting (CINV) means the dose is calculated based on a patient's Body Surface Area (BSA). The BSA is derived from the patient's height and weight, and this calculation determines the exact amount of medicine required per square meter of the patient's body surface.

---

Q: What is the main difference between Syndros and the capsule form of dronabinol (Marinol)?

Syndros is formulated as an an oral liquid solution, whereas the capsule form (Marinol) is an oral soft gelatin capsule. Furthermore, the DEA lists Syndros as a Schedule II controlled substance, while the capsule form is listed as a Schedule III controlled substance.

---

Q: How does the liquid form of Syndros compare to the capsule in terms of how fast it works?

Pharmacokinetic data indicates that peak concentrations of the active ingredient occur between 0.5 and 4 hours after taking the oral solution. This timing is consistent with the absorption rate reported for the capsule formulation.

---

Q: Is Syndros considered a controlled substance, and what does that classification mean for patients?

Syndros is listed by the U.S. Drug Enforcement Administration (DEA) as a Schedule II controlled substance. This classification indicates that the drug has a high potential for abuse but is also accepted for medical use under strict regulatory supervision.

---

Q: Can Syndros be used for appetite stimulation in people who do not have AIDS?

The regulatory labeling specifies that Syndros is approved for treating anorexia associated with weight loss in patients with AIDS. Use is described only for the two specific indications listed in the official product information.

---

Q: What is the potential risk of drug abuse or dependence associated with Syndros?

Due to its nature as a Schedule II controlled substance, official warnings advise healthcare providers to assess the risk for abuse or misuse in patients with a history of substance dependence. Additionally, physical dependence can develop with chronic use, potentially leading to a withdrawal syndrome upon abrupt cessation.

---

Q: How long does the effect of a dose of Syndros typically last?

The duration of the psychoactive effects is commonly reported as 4 to 6 hours. However, the intended appetite-stimulant effect may continue for 24 hours or longer after administration.

---

Q: Is the onset of effect for Syndros different when taken for appetite loss versus nausea?

Pharmacokinetic data shows that the peak concentration of the active ingredient is reached in the body between 0.5 and 4 hours after oral dosing, regardless of the indication for which the medicine is taken.

---

Q: Are there any reported cases of withdrawal symptoms after stopping Syndros?

Regulatory documents describe a withdrawal syndrome following the abrupt discontinuation of high doses used in studies. Symptoms noted included irritability, insomnia, restlessness, sweating, and hot flashes.

---

Q: What is the correct storage temperature for Syndros before and after the bottle is opened?

Unopened bottles of the oral solution must be stored in the refrigerator (2°C to 8°C or 36°F to 46°F). Once the bottle is opened, storage information permits it to be kept at room temperature (20°C to 25°C or 68°F to 77°F).

---

Q: How quickly must an opened bottle of Syndros be used before it should be discarded?

Official storage information states that once the bottle is opened, the oral solution must be used or discarded after 42 days (6 weeks). This time limit applies regardless of whether the bottle is kept refrigerated or at room temperature.

---

Q: What are the official guidelines regarding the use of marijuana or cannabis products while taking Syndros?

Syndros is a Schedule II controlled substance. Official labeling includes a general warning about potential additive central nervous system (CNS) effects when the medicine is taken concurrently with other CNS depressants, which may include certain cannabis products.

---

Q: Can Syndros be taken with other anti-nausea medications, and is there a risk of interaction?

Regulatory warnings cover interactions with CNS depressants and other agents that may cause additive hemodynamic instability (changes in heart rate or blood pressure). These categories may include certain anti-nausea agents, and close monitoring may be required.

---

Q: What are the signs of an overdose of Syndros?

Signs of an overdose are described in regulatory documents as an exaggerated extension of the known pharmacological effects. These effects can include severe intoxication, extreme changes in mood, reduced motor coordination, and altered perception.

---

Q: Does Syndros have any known effects on kidney or liver function?

The drug undergoes extensive hepatic metabolism (processing) in the liver by the CYP450 enzymes. Official labeling includes details on the known drug interactions related to these liver enzymes and their function.

---

Q: Is Syndros intended to be a short-term or long-term medication?

Official dosing schedules exist for both chronic use (AIDS-related anorexia) and episodic use (CINV). Regulatory studies have described outcomes for both short-term (CINV) and intermediate/longer-term (AIDS) research populations.

---

Q: Can Syndros be prescribed for conditions other than those listed on the FDA label?

Syndros is officially approved for the two specific indications listed in the regulatory labeling: AIDS-related anorexia and chemotherapy-induced nausea and vomiting. The drug is described only for these two conditions.

---

Q: Does the effectiveness of Syndros change over time with continued use?

Official pharmacodynamics indicate that tolerance (tachyphylaxis) can develop to some of the cardiovascular and central nervous system (CNS) effects with chronic use. However, this tolerance does not appear to develop to the intended appetite-stimulant effect.

Official Storage and Disposal Requirements

Syndros (dronabinol) oral solution is a Schedule II controlled substance, and its storage and disposal must strictly follow regulatory guidance to ensure stability and security.

Condition	Requirement (Temperature/Time)
Unopened Bottle	Refrigerator: 2 C to 8 C (36 F to 46 F)
Opened Bottle	Room Temperature: 20 C to 25 C (68 F to 77 F)
In-Use Stability	Discard unused portion 42 days after the date of first opening

Handling and Protection:

• Keep the bottle and the oral syringe in the supplied carton to protect the contents from light.
• The child-resistant cap must be tightly closed.
• Write the date the bottle is opened on both the bottle and carton.
• Keep Syndros and all medicines out of the reach of children.

Disposal Rules:

• As a Schedule II controlled substance, disposal must comply with high-security requirements established by the DEA.
• Discard any unused or expired portion through an authorized drug take-back program or official collection point, or follow specific instructions from the DEA or local law enforcement.